Showing 7191-7200 of 8826 results for "".
- NEA Promotes Eczema Awareness Month in Octoberhttps://practicaldermatology.com/news/nea-promotes-eczema-awareness-month-october/2468331/The National Eczema Association (NEA) will present Eczema Awareness Month throughout October to spread awareness about living with eczema, the organization announced in a press release. This year's awareness campaign puts eczema on display with real, up-close photos of community members' f
- New Deuruxolitinib Data to Be Presented at EADVhttps://practicaldermatology.com/news/new-deuruxolitinib-data-be-presented-eadv/2468304/Sun Pharma will present new clinical data on the JAK1/JAK2 inhibitor deuruxolitinib at the 2024 European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, Netherlands from September 25-28, the company announced. Deuruxolitinib, which Sun Pharma provides under the name LE
- Report: Nonsurgical Aesthetics Revenues Up 9%https://practicaldermatology.com/news/report-nonsurgical-aesthetics-revenues-9/2468303/Data and analytics solutions provider Guidepoint Qsight and investment banking and management consulting firm Skytale Group released a new report on the state of the aesthetics industry, highlighting the continued expansion of the US market. Combined nonsurgical revenues increased by 9% in
- Kenvue to Present New Data Sets at EADV Congresshttps://practicaldermatology.com/news/kenvue-present-new-data-sets-eadv-congress/2468301/Kenvue announced the presentation of seven new data sets at the 2024 European Academy of Dermatology and Venereology (EADV) Congress this week in Amsterdam, Netherlands. The studies will feature Kenvue’s Aveeno and Neutrogena brands, “demonstrating the key to improved skin and hair outcome
- New Photoprotection Data at EADV Congresshttps://practicaldermatology.com/news/new-photoprotection-data-eadv-congress/2468300/Kenvue announced the presentation of two new data sets relating to photoprotection at the 2024 European Academy of Dermatology and Venereology (EADV) Congress this week in Amsterdam, Netherlands. The studies will demonstrate "the key to improved skin and hair outcomes through proactive use
- Roflumilast Cream Shows Consistent Results in AD Across Skin Typeshttps://practicaldermatology.com/news/roflumilast-cream-shows-consistent-results-ad-across-skin-types/2468298/Newly published pooled analyses of the INTEGUMENT trials suggest that ZORYVE (roflumilast) cream 0.15% showed significant improvements in atopic dermatitis (AD) symptoms, regardless of race, ethnicity, or Fitzpatrick skin type. Results from the studies showed that higher percentages of pat
- Tirbanibulin Research for Actinic Keratosis to be Presented at EADVhttps://practicaldermatology.com/news/tirbanibulin-research-actinic-keratosis-be-presented-eadv/2468262/Almirall will present eight abstracts detailing the latest research on tirbanibulin for actinic keratosis at the 33rd Congress of the European Academy of Dermatology and Venereology (EADV), the company announced. The EADV takes place September 25-28 in Amsterdam, Netherlands. Almira
- sNDA Accepted for Roflumilast Foam 0.3% for Psoriasishttps://practicaldermatology.com/news/snda-accepted-roflumilast-foam-03-psoriasis/2468261/The US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for roflumilast foam 0.3%—a once-daily, next-generation phosphodiesterase-4 (PDE4) inhibitor branded ZORYVE by Arcutis Biotherapeutics, Inc.—for the treatment of adults and adolescents ages 12 and ov
- Bimekizumab-bkzx Approved for PsA, nr-axSpA, AShttps://practicaldermatology.com/news/bimekizumab-bkzx-approved-psa-nr-axspa/2468260/Bimekizumab-bkzx has been approved by the US Food and Drug Administration (FDA) for the treatment of adults with active psoriatic arthritis (PsA), adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and adults with active ankylosing spondyl
- Delgocitinib for CHE Gains EC Approval, FDA NDA Acceptancehttps://practicaldermatology.com/news/delgocitinib-che-gains-ec-approval-fda-nda-acceptance/2468259/Delgocitinib cream 20 mg/g (2%) reached major milestones in both the United States and Europe, LEO Pharma Inc. announced. The US Food and Drug Administration (FDA) accepted a filing for a New Drug Application (NDA) for LEO Pharma’s AnzupgoÒ for the treatment of adults with moderate-to-seve